On July 17, 2007, Rwanda became the first country to seek generic AIDS drugs under Canada's Access to Medicines Regime. Rwanda's intentions were detailed in a formal notification to the WTO. The notification states that Rwanda's Government Centre for the Treatment & Research on AIDS expects to import 260,000 packs of TriAvir manufactured in Canada by Apotex Inc. during the next two years and will not enforce rights provided under Part II Section 5 of the TRIPS Agreements that may have been granted in Rwanda with respect to the product. Under TRIPS, WTO countries, such as Canada, can authorize someone other than the patent holder to manufacture a lower cost version of a patented drug or medical device for export to developing countries that do not have the capacity to manufacture such products.

More information, please see: